CorMedix Inc
NASDAQ:CRMD

Watchlist Manager
CorMedix Inc Logo
CorMedix Inc
NASDAQ:CRMD
Watchlist
Price: 10.56 USD -0.75% Market Closed
Market Cap: 832m USD

CorMedix Inc
Revenue

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

CorMedix Inc
Revenue Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
CorMedix Inc
NASDAQ:CRMD
Revenue
$214.3m
CAGR 3-Years
1 189%
CAGR 5-Years
304%
CAGR 10-Years
95%
Johnson & Johnson
NYSE:JNJ
Revenue
$92.1B
CAGR 3-Years
10%
CAGR 5-Years
3%
CAGR 10-Years
3%
Bristol-Myers Squibb Co
NYSE:BMY
Revenue
$48B
CAGR 3-Years
1%
CAGR 5-Years
4%
CAGR 10-Years
11%
Pfizer Inc
NYSE:PFE
Revenue
$62.8B
CAGR 3-Years
-14%
CAGR 5-Years
9%
CAGR 10-Years
3%
Merck & Co Inc
NYSE:MRK
Revenue
$64.2B
CAGR 3-Years
3%
CAGR 5-Years
13%
CAGR 10-Years
5%
Eli Lilly and Co
NYSE:LLY
Revenue
$59.4B
CAGR 3-Years
27%
CAGR 5-Years
21%
CAGR 10-Years
12%
No Stocks Found

CorMedix Inc
Glance View

CorMedix, Inc. operates as a pharmaceutical and medical device company. The company is headquartered in Berkeley Heights, New Jersey and currently employs 29 full-time employees. The company went IPO on 2010-03-25. The firm is focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The firm's primary focus is on the development of its product candidate, DefenCath. The firm has in-licensed the rights to develop and commercialize its product candidate DefenCath. The DefenCath is a novel anti-infective solution intended for the reduction of catheter-related infections in patients requiring central venous catheters in clinical settings such as hemodialysis, total parenteral nutrition, and oncology. DefenCath product is available in Europe and other territories under the brand name Neutrolin.

CRMD Intrinsic Value
36.83 USD
Undervaluation 71%
Intrinsic Value
Price

See Also

What is CorMedix Inc's Revenue?
Revenue
214.3m USD

Based on the financial report for Sep 30, 2025, CorMedix Inc's Revenue amounts to 214.3m USD.

What is CorMedix Inc's Revenue growth rate?
Revenue CAGR 10Y
95%

Over the last year, the Revenue growth was 1 648%. The average annual Revenue growth rates for CorMedix Inc have been 1 189% over the past three years , 304% over the past five years , and 95% over the past ten years .

Back to Top